Skip to content

Madrigal Pharmaceuticals

US · MDGL #1355 by market cap Listed 2016
487.72 -8.73 -1.76%
Live - 5344 symbols - heartbeat 31s ago · 2026-10-08 07:10
Pre-market 498.89 +2.29%
After-hours 487.72 0.00%
Market cap
11.27B
P/B
21.52
EPS
-12.85
Reader sentiment Are you bullish or bearish on MDGL?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Wells Fargo Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $685
    Market Newswire · 2026/7/27
  • Rating change
    Wolfe Research Upgrades Madrigal Pharmaceuticals(MDGL.US) to Buy Rating, Announces Target Price $605
    Market Newswire · 2026/8/4
  • Rating change
    Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739
    Market Newswire · 2026/7/17
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)
    TipRanks · 2026/7/14
  • Rating change
    Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $962
    Market Newswire · 2026/8/4
  • Rating change
    Truist Financial Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating
    Market Newswire · 2026/7/14
  • Rating change
    Truist Financial Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $709
    Market Newswire · 2026/7/31
  • Rating change
    TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $644
    Market Newswire · 2026/7/31
  • Rating change
    H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620
    Market Newswire · 2026/7/31
  • Rating change
    BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542
    Market Newswire · 2026/7/14
  • Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962
    Market Newswire · 2026/9/30
  • Rating change
    UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669
    Market Newswire · 2026/7/22
  • Rating change
    Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964
    Market Newswire · 2026/7/13
  • Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725
    Market Newswire · 2026/9/23
  • Goldman Sachs Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $704
    Market Newswire · 2026/9/24
  • Rating change
    CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $612
    Market Newswire · 2026/8/12
  • Form 144 | Madrigal Pharmaceuticals(MDGL.US) Director Proposes to Sell 25.83 Million in Common Stocks
    Market Newswire · 2026/9/29
  • Rating change
    BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553
    Market Newswire · 2026/7/22
  • Rating change
    CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $587
    Market Newswire · 2026/7/29
  • Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $364.3M, Vs. FactSet Est of $352.1M
    MT Newswires · 2026/7/30

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:10:38 · For reference only, not investment advice and not tailored to your situation.